Taysha, Catalent Partner to Advance Gene Therapies for Batten, Other Disorders

Taysha, Catalent Partner to Advance Gene Therapies for Batten, Other Disorders

282277

Taysha, Catalent Partner to Advance Gene Therapies for Batten, Other Disorders

Taysha Gene Therapies announced that it has joined with Catalent, a pharmaceutical services provider, to support production of its potential gene therapies for disorders that include CLN1 Batten disease and Rett syndrome. “Through this partnership, we will be able to enhance our existing manufacturing capabilities to support Taysha’s broad gene therapy pipeline,” R.A. Session, the president, founder, and CEO of Taysha, said in a press release. Taysha currently has over a dozen experimental therapies in various stages…

You must be logged in to read/download the full post.